Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 11 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Kidney Metabolic
Early SGLT2i/MRA Use Benefits Suspected HF Patients
Added: 2 months ago Source:  Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes… View more

Intervention

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC 24: MRAs in Heart Failure
Author(s): Added: 1 year ago
ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT… View more

Heart Failure
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 11 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
Finerenone Approved in EU for HF with LVEF ≥40%
Added: 3 weeks ago Source:  Heart Failure Academy
The European Commission has approved the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia) for the treatment of adults with symptomatic chronic heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.¹ The approval is based on positive results from the Phase III Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients… View more

Heart Failure
Spironolactone versus Eplerenone for Resistant Hypertension
Author(s): Hanselim Lim , Wuri Noviar Hamdani Added: 2 years ago

Prevention & Chronic Conditions
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 1 year ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
Faiez Zannad
Research Area(s) / Expertise: Job title: Professor Emeritus; Founder and Chairman of CVCT Société Civile
Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research… View more